Bürli Roland W, McMinn Dustin, Kaizerman Jacob A, Hu Wenhao, Ge Yigong, Pack Quinn, Jiang Vernon, Gross Matthew, Garcia Martin, Tanaka Richard, Moser Heinz E
Genesoft Pharmaceuticals Inc., 7300 Shoreline Court, South San Francisco, CA 94080, USA.
Bioorg Med Chem Lett. 2004 Mar 8;14(5):1253-7. doi: 10.1016/j.bmcl.2003.12.042.
Novel DNA minor-groove binding ligands with a promising antibacterial profile are described. Apart from excellent in vitro potency against multiple Gram-positive bacterial strains such as methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant Enterococcus faecalis (VRE), and penicillin-intermediate Streptococcus pneumoniae (PISP), a small subset of compounds was active against Gram-negative bacteria such as Escherichia coli (E. coli).
描述了具有良好抗菌特性的新型DNA小沟结合配体。除了对多种革兰氏阳性细菌菌株，如耐甲氧西林金黄色葡萄球菌（MRSA）、耐万古霉素粪肠球菌（VRE）和青霉素中介肺炎链球菌（PISP）具有优异的体外活性外，一小部分化合物对革兰氏阴性细菌，如大肠杆菌（E. coli）也有活性。
